Prospective study of the association between NAT2 gene haplotypes and severe adverse events with sulfasalazine therapy in patients with rheumatoid arthritis

Journal of Rheumatology

Volumn 35, Issue 4, 2008, Pages 724-725

  Soejima, Makoto ^a   Kawaguchi, Yasushi ^a   Hara, Masako ^a   Kamatani, Naoyuki ^a  

^a TOKYO WOMEN'S MEDICAL UNIVERSITY   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

ARYLAMINE ACETYLTRANSFERASE; GENOMIC DNA; SALAZOSULFAPYRIDINE;

ADULT; AGED; CASE REPORT; DISEASE SEVERITY; DRUG ERUPTION; DRUG FEVER; FEMALE; GENETIC ASSOCIATION; GENETIC POLYMORPHISM; GENETIC VARIABILITY; GENOTYPE; HAPLOTYPE; HOSPITALIZATION; HUMAN; JAPANESE; LETTER; MALE; PANCYTOPENIA; PRIORITY JOURNAL; PROSPECTIVE STUDY; RHEUMATOID ARTHRITIS; SINGLE NUCLEOTIDE POLYMORPHISM; STEVENS JOHNSON SYNDROME;

ADULT; AGED; ANTIRHEUMATIC AGENTS; ARTHRITIS, RHEUMATOID; ARYLAMINE N-ACETYLTRANSFERASE; FEMALE; GENETIC PREDISPOSITION TO DISEASE; HAPLOTYPES; HUMANS; MALE; PROSPECTIVE STUDIES; SULFASALAZINE;

EID: 41849110551     PISSN: 0315162X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Letter

References (10)

1. Smolen JS, Kalden JR, Scott DL, et al. Efficacy and safety of leflunomide compared with placebo and sulphasalazine in active rheumatoid arthritis: a double-blind, randomised, multicentre trial, European Leflunomide Study Group. Lancet 1999;353:259-66.
2. Ikari K, Momohara S. Images in clinical medicine. Bone changes in rheumatoid arthritis. N Engl J Med 2005;353:e13.
3. Krause D, Schleusser B, Herborn G, Rau R. Response to methotrexate treatment is associated with reduced mortality in patients with severe rheumatoid arthritis. Arthritis Rheum 2000;43:14-21.
4. Tanaka E, Taniguchi A, Urano W, et al. Adverse effects of sulfasalazine in patients with rheumatoid arthritis are associated with diplotype configuration at the N-acetyltransferase 2-gene. J Rheumatol 2002;29:2492-9.
5. Taniguchi A, Urano W, Tanaka E, et al. Validation of the associations between single nucleotide polymorphisms or haplotypes and responses to disease-modifying antirheumatic drugs in patients with rheumatoid arthritis: a proposal for prospective pharmacogenomic study in clinical practice. Pharmacogenet Genomics 2007;17:383-90.
6. Arnett FC, Edworthy SM, Bloch DA, et al. The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis. Arthritis Rheum 1988;31:315-24.
7. Soejima M, Sugiura T, Kawaguchi Y, et al. Association of the diplotype configuration at the N-acetyltransferase 2 gene with adverse events with co-trimoxazole in Japanese patients with systemic lupus erythematosus. Arthritis Res Ther 2007;9:R23.
8. Furihata S, Ito T, Kamatani N. Test of association between haplotypes and phenotypes in case-control studies: examination of validity of the application of an algorithm for samples from cohort or clinical trials to case-control samples using simulated and real data. Genetics 2006;174:1505-16.
9. Ito T, Inoue E, Kamatani N. Association test algorithm between a qualitative phenotype and a haplotype or haplotype set using simultaneous estimation of haplotype frequencies, diplotype configurations and diplotype-based penetrances. Genetics 2004;168:2339-48.
10. Mahid SS, Colliver DW, Crawford NPS, et al. Characterization of N-acetyltransferase 1 and 2 polymorphisms and haplotype analysis for inflammatory bowel disease and sporadic colorectal carcinoma. BMC Medical Genetics 2007;8:28.